AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 83 min read$TLRY

Tilray Brands (TLRY) Shares Slip Premarket After Q1 Revenue Miss

Tilray Brands (TLRY) reported Q1 revenue of $257.2M, up 23% YoY but below estimates by $9.7M. Cannabis revenue declined 13%, while beverage and distribution segments grew. The company posted a net loss of $3.0M but beat adjusted EPS estimates by $0.16. Tilray's P/S ratio is 0.45, below historical and industry averages, reflecting market skepticism about future growth.

Original reporting
gurufocus.com
Published Oct 8, 2026, 12:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TLRY
Bearish
medium confidence
Mentioned
$TLRY
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$TLRYBearishMed
01

Why it matters

Revenue miss drives immediate price decline, but the low P/S ratio and EPS beat suggest potential upside for contrarian investors.

02

Market read

First‑report earnings release for a micro‑cap cannabis firm; provides fresh data for short‑term traders.

03

What to watch

Strong beverage and distribution performance may offset cannabis weakness in the longer term.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Tilray Brands reported fiscal Q1 results with mixed performance across its segments.

Company-level read

Ticker impact

$TLRYBearishMedium confidence
Context

Q1 revenue missed expectations while adjusted EPS beat estimates, causing pre‑market share decline.

Expected impact

downward pressure as investors weigh the revenue miss against the EPS beat

Evidence & confidence

Revenue miss signals slower top‑line growth; EPS beat may not offset concerns, leading to modest sell‑off.

Market effects

Sector

Cannabis and related consumer segments may see broader scrutiny after TLRY's miss.

Regional

North American cannabis stocks could face short‑term pressure.

Global

Limited to investors tracking cannabis and specialty beverage distributors.

Counterpoint

What could challenge this read

The EPS beat and low valuation multiples could attract value‑oriented buyers despite the revenue miss.

Key entities

  • company
    Tilray Brands Inc

    Canadian cannabis and beverage company reporting Q1 results.

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

3 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min